Drugs / RGL-193
last change Dec 2024 re-read 3 minutes ago

RGL-193

Developed for
Parkinson disease
Investigated by
Second Affiliated Hospital of Soochow University · Shanghai Regenelead Therapies Co., Ltd.

Trials 1

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT06195124 Dec 2023 → Dec 2024 Parkinson disease Second Affiliated Hospital of Soochow University Unknown No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RGL-193 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06195124 ↗